Interpretation of clinical trial results of platinib in the treatment of specific types of lung cancer

Introduction: Platinib is a selective RET inhibitor specifically designed to treat patients with non-small cell lung cancer (NSCLC) carrying RET gene fusions. In clinical trials, platinib has demonstrated significant efficacy and acceptable safety, providing a new treatment option for patients with specific types of lung cancer and is expected to become a new standard of care. Platinib is a prescription drug that needs to be treated under the guidance of a physician experienced in lung cancer treatment.

How Platinib works

is a receptor tyrosine kinase RET inhibitor that selectively inhibits RET kinase activity, dose-dependently inhibits the phosphorylation of RET and its downstream molecules, and effectively inhibits the proliferation of cells expressing RET (wild type and multiple mutants). The drug is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Clinical trial results of platinib for the treatment of certain types of lung cancer

Efficacy was confirmed in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC in a study in which patients received platinib until disease progression or unacceptable toxicity. Among 107 treatment-naïve patients, the ORR was 78% and the median DOR was 13.4 months. Among 130 patients who had previously received platinum-based chemotherapy, the patient's ORR reached 63%, and the median DOR was 38.8 months. In another study, platinib treatment achieved an ORR of 66.7% in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy. Among patients who have not received systemic treatment, the ORR is as high as 80%, which generally shows that platinib can bring significant tumor response to patients.

Safety Data

The most common adverse events associated with platinib include increased aspartate aminotransferase, decreased neutrophil count, anemia, decreased white blood cell count, constipation, hypertension, fatigue, musculoskeletal pain, and diarrhea. Most of these adverse events are manageable mild to moderate. 10.3% of patients discontinued platinib due to related adverse events, indicating that although the safety profile of platinib is generally manageable, patients still need to be closely monitored and managed.